Skip to Content
Merck
  • The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis.

The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis.

Journal of neuroimmunology (2005-07-30)
Francesco Lolli, Benedetta Mazzanti, Marta Pazzagli, Elisa Peroni, Maria Claudia Alcaro, Giuseppina Sabatino, Roberta Lanzillo, Vincenzo Brescia Morra, Lucio Santoro, Claudio Gasperini, Stefania Galgani, Mario Milco D'Elios, Valentina Zipoli, Stefano Sotgiu, Maura Pugliatti, Paolo Rovero, Mario Chelli, Anna Maria Papini
PMID16051375
ABSTRACT

Synthetic glycopeptides have the potential to detect antibodies in multiple sclerosis (MS). In the present study, we analyzed the antibodies (IgM class, IgG class and IgG subclasses) to the synthetic glycopeptide CSF114(Glc) in the serum of 186 MS patients, 166 blood donors (BDs), 25 patients affected by meningitis/encephalitis, 41 affected by systemic lupus erythematosus (SLE) and 49 affected by rheumatoid arthritis (RA). The IgM antibody level to CSF114(Glc) was significantly increased in MS patients versus BDs (p<0.001) or versus other autoimmune diseases (SLE or RA, p<0.001). The IgG response was restricted to the subclass IgG2. IgM antibodies to CSF114(Glc) were found in 30% of relapsing/remitting MS patients and, at lower levels, in subjects affected by meningitis/encephalitis. The study of antibodies to CSF114(Glc) is a new, potential immunological marker of MS.